{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:15:18Z","timestamp":1781619318614,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Frankfurt"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The optimal time point of salvage radiotherapy (sRT) for biochemical recurrence (BCR) following radical prostatectomy is still under debate. Current European guidelines recommend salvage intensity-modulated and image\u2010guided radiotherapy for men with two consecutive PSA rises. However, no specific PSA threshold for initiation time is recommended. Nonetheless, lower PSA level may be associated with better cancer-control outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Relying on the University Cancer Center Frankfurt database, we evaluated differences in metastasis-free survival (MFS) among patients treated with early sRT (&lt;\u20090.5 ng\/ml) vs. sRT at PSA\u2009\u2265\u20090.5ng\/ml. Subgroup analyses addressed sRT patients with high-risk features for indication of adjuvant radiation therapy, including Gleason score 8\u201310 and\/or pT3\u20134 stage and\/or pN1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 190 sRT patients, 69% received early sRT at median PSA 0.24ng\/ml vs. 0.89ng\/ml. MFS was significantly better for early sRT patients, relative to sRT at PSA\u2009&gt;\u20090.5 ng\/ml (hazard ratio [HR]: 8.44,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Similarly, sRT patients with high-risk features also had significant better MFS at sRT with PSA\u2009&lt;\u20090.5ng\/ml (HR: 12.69,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). After additional multivariable adjustment, early sRT at PSA\u2009&lt;\u20090.5ng\/ml was independently associated with better MFS outcomes for all patients (HR: 8.2) and high-risk sRT subgroups (HR: 55.6, both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Finally, we validated the initiation of sRT at an even lower cut-off of a PSA level\u2009\u2264\u20090.25ng\/ml. However, this did not result in a significantly different outcomes, probably due to sample size limitations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results validate European guidelines\u2019 recommendation to initiate sRT at low PSA levels\u2009&lt;\u20090.5ng\/ml providing better MFS, especially in patients with high-risk features, refusing adjuvant radiation therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-025-05840-w","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:39:13Z","timestamp":1763753953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of PSA level at salvage radiotherapy on metastasis-free survival following radical prostatectomy"],"prefix":"10.1007","volume":"43","author":[{"given":"Mike","family":"Wenzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Burdenski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Tselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brandts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"K\u00f6llermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Humke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Siech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Hoeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K. H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"5840_CR1","unstructured":"Cornford P, Tilki D, van den Bergh RCN et al EAU Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3"},{"key":"5840_CR2","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","volume":"396","author":"CL Vale","year":"2020","unstructured":"Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, Sargos P, Sydes MR, Brawley C, Brihoum M, Brown C, Chabaud S, Cook A, Forcat S, Fraser-Browne C, Latorzeff I, Parmar MKB, Tierney JF (2020) Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet (London England) 396:1422\u20131431","journal-title":"Lancet (London England)"},{"key":"5840_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","volume":"66","author":"T Wiegel","year":"2014","unstructured":"Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, St\u00f6rkel S, Willich N, Semjonow A, St\u00f6ckle M, R\u00fcbe C, Rebmann U, K\u00e4lble T, Feldmann HJ, Wirth M, Hofmann R, Engenhart-Cabillic R, Hinke A, Hinkelbein W, Miller K (2014) Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96\u2013\u200902\/AUO AP 09\/95 trial. Eur Urol 66:243\u2013250","journal-title":"Eur Urol"},{"key":"5840_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.eururo.2019.07.001","volume":"76","author":"G Hackman","year":"2019","unstructured":"Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T, Luukkaala T, Salonen A, Isotalo T, P\u00e9tas A, Hendolin N, Bostr\u00f6m PJ, Aaltomaa S, Lehtoranta K, Hellstr\u00f6m P, Riikonen J, Korpela M, Minn H, Kellokumpu-Lehtinen P-L, Pukkala E, Hemminki A (2019) Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension. Eur Urol 76:586\u2013595","journal-title":"Eur Urol"},{"key":"5840_CR5","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","volume":"181","author":"IM Thompson","year":"2009","unstructured":"Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181:956\u2013962","journal-title":"J Urol"},{"key":"5840_CR6","doi-asserted-by":"crossref","unstructured":"Tilki D, Preisser F, Thamm R, Pompe RS, Chun FK-H, Graefen M, Siegmann A, B\u00f6hmer D, Budach V, Wiegel T (2022) Salvage radiotherapy versus observation for biochemical recurrence following radical prostatectomy for prostate cancer: a matched pair analysis. Cancers 14","DOI":"10.3390\/cancers14030740"},{"key":"5840_CR7","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1016\/j.juro.2009.08.027","volume":"182","author":"SA Boorjian","year":"2009","unstructured":"Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML (2009) Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol 182:2708\u20132714","journal-title":"J Urol"},{"key":"5840_CR8","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","volume":"299","author":"BJ Trock","year":"2008","unstructured":"Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760\u20132769","journal-title":"JAMA"},{"key":"5840_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","volume":"396","author":"CC Parker","year":"2020","unstructured":"Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, Cross W, Logue J, Parulekar W, Payne H, Persad R, Pickering H, Saad H, Anderson J, Bahl A, Bottomley D, Brasso K, Chahal R, Cooke PW, Eddy B, Gibbs S, Goh C, Gujral S, Heath C, Henderson A, Jaganathan R, Jakobsen H, James ND, Kanaga Sundaram S, Lees K, Lester J, Lindberg H, Money-Kyrle J, Morris S, O\u2019Sullivan J, Ostler P, Owen L, Patel P, Pope A, Popert R, Raman R, R\u00f8der MA, Sayers I, Simms M, Wilson J, Zarkar A, Parmar MKB, Sydes MR (2020) Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet (London England) 396:1413\u20131421","journal-title":"Lancet (London England)"},{"key":"5840_CR10","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","volume":"21","author":"A Kneebone","year":"2020","unstructured":"Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, Williams SG, Brown C, Delprado W, Haworth A, Joseph DJ, Martin JM, Matthews JHL, Millar JL, Sidhom M, Spry N, Tang CI, Turner S, Wiltshire KL, Woo HH, Davis ID, Lim TS, Pearse M (2020) Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 21:1331\u20131340","journal-title":"Lancet Oncol"},{"key":"5840_CR11","doi-asserted-by":"crossref","unstructured":"Parker CC, Petersen PM, Cook AD, Clarke NW, Catton C, Cross WR, Kynaston H, Parulekar WR, Persad RA, Saad F, Bower L, Durkan GC, Logue J, Maniatis C, Noor D, Payne H, Anderson J, Bahl AK, Bashir F, Bottomley DM, Brasso K, Capaldi L, Chung C, Cooke PW, Donohue JF, Eddy B, Heath CM, Henderson A, Henry A, Jaganathan R, Jakobsen H, James ND, Joseph J, Lees K, Lester J, Lindberg H, Makar A, Morris SL, Oommen N, Ostler P, Owen L, Patel P, Pope A, Popert R, Raman R, Ramani V, R\u00f8der A, Sayers I, Simms M, Srinivasan V, Sundaram S, Tarver KL, Tran A, Wells P, Wilson J, Zarkar AM, Parmar MKB, Sydes MR (2024) Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). Ann Oncol: Off J Eur Soc Med Oncol 35:656\u2013666","DOI":"10.1016\/j.annonc.2024.03.010"},{"key":"5840_CR12","doi-asserted-by":"crossref","unstructured":"Terlizzi M, Limkin EJ, Moukasse Y, Blanchard P (2022) Adjuvant or salvage radiation therapy for prostate cancer after prostatectomy: current status, controversies and perspectives. Cancers 14","DOI":"10.3390\/cancers14071688"},{"key":"5840_CR13","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","volume":"380","author":"M Bolla","year":"2012","unstructured":"Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, Reijke TMde, Verbaeys A, Bosset J-F, van Velthoven R, Colombel M, van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans K, Collette L (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (London England) 380:2018\u20132027","journal-title":"Lancet (London England)"},{"key":"5840_CR14","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","volume":"34","author":"RD Tendulkar","year":"2016","unstructured":"Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ (2016) Contemporary update of a Multi-Institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol: Off J Am Soc Clin Oncol 34:3648\u20133654","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"5840_CR15","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.22.02489","volume":"41","author":"D Tilki","year":"2023","unstructured":"Tilki D, Chen M-H, Wu J, Huland H, Graefen M, Mohamad O, Cowan JE, Feng FY, Carroll PR, D\u2019Amico AV (2023) Prostate-Specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death. J Clin Oncol: Off Am Soc Clin Oncol 41:2428\u20132435","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"5840_CR16","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","volume":"20","author":"C Carrie","year":"2019","unstructured":"Carrie C, Magn\u00e9 N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange J-L, Supiot S, Belkacemi Y, Peiffert D, Allouache N, Dubray BM, Servagi-Vernat S, Suchaud J-P, Crehange G, Guerif S, Brihoum M, Barbier N, Graff-Cailleaud P, Ruffion A, Dussart S, Ferlay C, Chabaud S (2019) Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol 20:1740\u20131749","journal-title":"Lancet Oncol"},{"key":"5840_CR17","doi-asserted-by":"crossref","unstructured":"Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, van Poppel H, Wiegel T, Briganti A (2016) Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy. Eur Urol 69, 728\u2013733","DOI":"10.1016\/j.eururo.2015.10.009"},{"key":"5840_CR18","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","volume":"25","author":"AJ Stephenson","year":"2007","unstructured":"Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol: Off J Am Soc Clin Oncol 25:2035\u20132041","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"5840_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0034-1395656","volume":"46","author":"D Bartkowiak","year":"2015","unstructured":"Bartkowiak D, Schrader AJ, Wiegel T (2015) Adjuvante vs. Salvage-Strahlentherapie Nach Radikaler prostatektomie. Aktuelle Urologie 46:52\u201358","journal-title":"Aktuelle Urologie"},{"key":"5840_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1200\/JCO.2003.12.043","volume":"21","author":"MS Katz","year":"2003","unstructured":"Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA (2003) Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol: Off J Am Soc Clin Oncol 21:483\u2013489","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"5840_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1607529","volume":"376","author":"WU Shipley","year":"2017","unstructured":"Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary J-P, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CAF, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376:417\u2013428","journal-title":"N Engl J Med"},{"key":"5840_CR22","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.eururo.2013.08.013","volume":"65","author":"D Pfister","year":"2014","unstructured":"Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, van Poppel H, Roach M, Stephenson A, Wiegel T, Zelefsky MJ (2014) Early salvage radiotherapy following radical prostatectomy. Eur Urol 65:1034\u20131043","journal-title":"Eur Urol"},{"key":"5840_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/pros.24452","volume":"83","author":"EE Lee","year":"2023","unstructured":"Lee EE, Singh T, Hu C, Han M, Deville C, Halthore JR, Greco A, Tran S, DeWeese P, Song T (2023) The impact of salvage radiotherapy initiation at PSA\u2009\u2264\u20090.5 ng\/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy. Prostate 83:190\u2013197","journal-title":"Prostate"},{"key":"5840_CR24","first-page":"769","volume":"33","author":"C W\u00fcrnschimmel","year":"2022","unstructured":"W\u00fcrnschimmel C, Wenzel M, Chierigo F, Flammia RS, Horlemann B, Tian Z, Saad F, Briganti A, Shariat SF, Gallucci M, Suardi N, Chun FKH, Tilki D, Graefen M, Karakiewicz PI (2022) Radiation therapy after radical prostatectomy is associated with higher other-cause mortality. Cancer Causes Control: CCC 33:769\u2013777","journal-title":"Cancer Causes Control: CCC"},{"key":"5840_CR25","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/pros.24169","volume":"81","author":"M Wenzel","year":"2021","unstructured":"Wenzel M, W\u00fcrnschimmel C, Chierigo F, Tian Z, Shariat SF, Terrone C, Saad F, Tilki D, Graefen M, Mandel P, Kluth LA, Chun FKH, Karakiewicz PI (2021) Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy. Prostate 81:728\u2013735","journal-title":"Prostate"},{"key":"5840_CR26","doi-asserted-by":"crossref","unstructured":"Wenzel M, Hussein R, Maurer T, Karakiewicz PI, Tilki D, Graefen M, W\u00fcrnschimmel C (2022) PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy. Urol Oncol 40:7.e1\u20137.e8","DOI":"10.1016\/j.urolonc.2021.06.008"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05840-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05840-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05840-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:19:33Z","timestamp":1781615973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05840-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5840"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05840-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6718321\/v1","asserted-by":"object"}]},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The current study was in accordance with the Declaration of Helskini. Local Review of the ethics board was approved.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No informed consent was necessary according to the approval of the study by the ethic committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"713"}}